Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent...
Mainz, Germany, August 04, 2010 - A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in...
View ArticleTetraLogic Pharmaceuticals COMPLETES $32 Million SERIES C FINANCING
Malvern, PA, August 10, 2010 - TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series...
View ArticleOrphagen Pharmaceuticals Awarde Federal Grant for Adrenocortical and Prostate...
San Diego, August 10, 2010 - Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of...
View ArticleHana Biosciences Reports Second Quarter 2010 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug 13, 2010 -- Hana Biosciences Inc. (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial...
View ArticleThe Institute of Cancer Research and Horizon Discovery to Collaborate on...
August 27, 2010 - The Institute of Cancer Research (ICR) and Horizon Discovery (Horizon) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that...
View ArticleIdera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration...
CAMBRIDGE, Mass., Aug 27, 2010 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck...
View ArticleIdera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration...
CAMBRIDGE, Mass.--August 27, 2010--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck...
View ArticleSciBase successfully achieves clinical study objectives
August 30, 2010--Swedish medtech company SciBase is in the final stage of development with its unique method for first line detection of malignant melanoma. A clinical study has recently been...
View ArticleEISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR...
August 30, 2010 - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has received notification from the U.S. Food...
View ArticlePublication of Phase II trial results of NGR-hTNF in liver cancer by the...
Milan (Italy), August 31, 2010 - MolMed S.p.A. (Milan:MLM) announces that the positive results of a phase II trial of its investigational anticancer drug NGR-hTNF in liver cancer have been...
View Article
